Background on the Phase 2 Study of Ponatinib/Blinatumomab in Ph+ ALL
Fadi Haddad, MD, discusses the background of a phase 2 study of blinatumomab in combination with ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Updated Findings of Ponatinib/Blinatumomab Combo in Ph+ ALL are Encouraging
Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology.